Eupraxia Pharmaceuticals Inc EPRX

TOR: EPRX | ISIN: CA29842P1053   16/07/2025
7,430 CAD (+1,36%)
(+1,36%)   16/07/2025

20 maart 2025 · Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results · Persbericht

11 september 2024 · Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis · Persbericht

11 september 2024 · Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis · Persbericht

4 september 2024 · Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference · Persbericht

4 september 2024 · Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference · Persbericht

7 augustus 2024 · Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results · Persbericht

2 augustus 2024 · Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility · Persbericht

2 augustus 2024 · Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility · Persbericht

8 juli 2024 · Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo · Persbericht

8 juli 2024 · Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo · Persbericht

3 juli 2024 · Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024 · Persbericht

3 juli 2024 · Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024 · Persbericht

6 juni 2024 · Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders · Persbericht

6 juni 2024 · Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders · Persbericht

5 juni 2024 · Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024 · Persbericht

5 juni 2024 · Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024 · Persbericht

23 mei 2024 · Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis · Persbericht

23 mei 2024 · Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis · Persbericht

22 mei 2024 · Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024 · Persbericht

22 mei 2024 · Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024 · Persbericht

Mijn selecties